Alpha-2 Adrenergic Receptors and Attention-Deficit/Hyperactivity Disorder
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Pharmacologic management of attention-deficit/hyperactivity disorder (ADHD) has expanded beyond stimulant medications to include α-2 adrenergic agonists. These agents exert their actions through presynaptic stimulation and likely involve facilitation of dopamine and noradrenaline neurotransmission, both of which are thought to play critical roles in the pathophysiology of ADHD. Furthermore, frontostriatal dysfunction giving rise to neuropsychological weaknesses has been well-established in patients with ADHD and may explain how α-2 agents exert their beneficial effects. In the following review, we consider relevant neurobiological underpinnings of ADHD with respect to why α-2 agents may be effective in treating this condition. We also review new formulations of α-2 agonists, emerging data on their use in ADHD, and implications for clinical practice. Integrating knowledge of pathophysiologic mechanisms and mechanisms of drug action may inform our medication choices and facilitate treatment of ADHD and related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Goldman-Rakic, P. S. (1996) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1996.0129 · Cited by 1,072
sagvolden, T., johansen, E. B., aase, H., & russell, V. A. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000075 · Cited by 1,035
Candidate gene studies of ADHD: a meta-analytic review
Gizer, I. R., Ficks, C., & Waldman, I. D. (2009) · Human Genetics · doi:10.1007/s00439-009-0694-x · Cited by 1,020
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Barkley, R. A., Grodzinsky, G., & DuPaul, G. J. (1992) · Journal of Abnormal Child Psychology · doi:10.1007/bf00916547 · Cited by 724 · cited 1×
“There is general agreement that ADHD involves weakened PFC function, and medications that treat ADHD ameliorate PFC deficits [ 25 ].”
BackgroundFrazier, T. W., Youngstrom, E. A., Glutting, J. J., & Watkins, M. W. (2007) · Journal of Learning Disabilities · doi:10.1177/00222194070400010401 · Cited by 700
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Arnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391
U’PRICHARD, D. C., BECHTEL, W. D., ROUOT, B. M., & SNYDER, S. H. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11406-5 · Cited by 384
Arnsten, A. F. T. (2009) · CNS Drugs · doi:10.2165/00023210-200923000-00005 · Cited by 371
Kessler, R. C., Adler, L., Ames, M., Barkley, R. A., Birnbaum, H., Greenberg, P., Johnston, J. A., Spencer, T., & ??st??n, T. B. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000166863.33541.39 · Cited by 335
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Sallee, F. R., Lyne, A., Wigal, T., & McGough, J. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0080 · Cited by 306 · cited 1×
“[ 75 ]. A second 2-year open study following a randomized controlled trial found monotherapy with GXR to be efficacious and well-tolerated, again in the context of greater than 75% dropout.”
BackgroundCoull, J. T., Nobre, A. C., & Frith, C. D. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.1.73 · Cited by 298 · cited 1×
“One study examined the effects of guanfacine on performance and task-related brain activation as measured by functional MRI during a task of visuospatial attention with variably cued choice reactions and found no changes in cognitive function [ 53 ].”
MethodA meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder
CONNOR, D. F., FLETCHER, K. E., & SWANSON, J. M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199912000-00017 · Cited by 297
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
Chamberlain, S. R., del Campo, N., Dowson, J., Müller, U., Clark, L., Robbins, T. W., & Sahakian, B. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.003 · Cited by 288 · cited 1×
“Similarly, Chamberlain et al. [ 61 ] showed that atomoxetine, a selective noradrenaline reuptake inhibitor, improves response inhibition and working memory deficits in adults with ADHD.”
BackgroundBiederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900017107 · Cited by 270 · cited 1×
“Slight changes in pulse, blood pressure, and QT interval were clinically insignificant. Syncope occurred in two individuals [ 76 ].”
BackgroundBirnbaum, H. G., Kessler, R. C., Lowe, S. W., Secnik, K., Greenberg, P. E., Leong, S. A., & Swensen, A. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079904x20303 · Cited by 237
Taylor, F. B., & Russo, J. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00015 · Cited by 189
Li, B.-M., & Mei, Z.-T. (1994) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(05)80034-2 · Cited by 186
Arnsten, A. F. T., & Contant, T. A. (1992) · Psychopharmacology · doi:10.1007/bf02245302 · Cited by 168 · cited 1×
“Working memory improvement was accompanied by reduced distractibility [ 36 ] and enhanced regional cerebral blood flow in the dorsolateral PFC (DLPFC) [37].”
BackgroundLi, B. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00070-6 · Cited by 162 · cited 1×
“Blockade of α-2A adrenoceptors in monkey PFC with yohimbine profoundly impaired spatial working memory [38] and eroded delay-related firing of PFC neurons [ 39 ].”
BackgroundUhlén, S., & Wikberg, J. E. S. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90299-6 · Cited by 141
Ramos, B. P., Stark, D., Verduzco, L., van Dyck, C. H., & Arnsten, A. F. T. (2006) · Learning & Memory · doi:10.1101/lm.298006 · Cited by 124 · cited 2×
“The α-2 agonists clonidine and guanfacine mimic NE actions in the PFC through the stimulation of α-2A receptors on PFC neurons [ 19 ].”
BackgroundSagvolden (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-41 · Cited by 94
Lack of effects of guanfacine on executive and memory functions in healthy male volunteers
Müller, U., Clark, L., Lam, M. L., Moore, R. M., Murphy, C. L., Richmond, N. K., Sandhu, R. S., Wilkins, I. A., Menon, D. K., Sahakian, B. J., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0078-4 · Cited by 73 · cited 1×
“Similarly, clonidine had no effect on cognitive performance in a planning task [54], and Muller et al. [ 55 ] found no effects on tests of memory, planning, motor inhibition, and executive attention after guanfacine administration.”
BackgroundThe effects of guanfacine on context processing abnormalities in schizotypal personality disorder
McClure, M. M., Barch, D. M., Romero, M. J., Minzenberg, M. J., Triebwasser, J., Harvey, P. D., & Siever, L. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.034 · Cited by 70
Kieling, C., Genro, J. P., Hutz, M. H., & Rohde, L. A. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30636 · Cited by 65 · cited 1×
“Similarly, variation in the DBH gene has been related to deficits in executive function and the ability to sustain attention [64, 65 ].”
BackgroundAlpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness
Scahill, L. (2009) · CNS Drugs · doi:10.2165/00023210-200923000-00006 · Cited by 58
Wang, M., Tang, Z.-X., & Li, B.-M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.062 · Cited by 31
Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals
Clerkin, S. M., Schulz, K. P., Halperin, J. M., Newcorn, J. H., Ivanov, I., Tang, C. Y., & Fan, J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.013 · Cited by 28 · cited 1×
“These results provide supporting evidence that guanfacine selectively potentiates activation to preparatory cues in the DLPFC and anterior cerebellar regions as part of a broader thalamo-frontal-striatal network specialized for response preparation [ 52 ].”
ResultSwartz, B. E., McDonald, C. R., Patel, A., & Torgersen, D. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633461 · Cited by 20
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder
Corona, J. C. (2020) · Antioxidants · doi:10.3390/antiox9111039 · Cited by 163
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Thapa, R., Pokorski, I., Ambarchi, Z., Thomas, E., Demayo, M., Boulton, K., Matthews, S., Patel, S., Sedeli, I., Hickie, I. B., et al. (2021) · Autism Research · doi:10.1002/aur.2437 · Cited by 44
Metadata
- Authors
- Cinnamon Bidwell, L., Dew, R. E., & Kollins, S. H.
- Venue
- Current Psychiatry Reports
- Published
- 2010-07-23
- Volume
- 12
- Issue
- 5
- Pages
- 366-373
- ISSN
- 1523-3812 (ISSN-L)
- 1535-1645
- OpenAlex
- W2172029282
- Cited by
- 53
- References
- 35
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.